Search

Your search keyword '"Victoria Barghout"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Victoria Barghout" Remove constraint Author: "Victoria Barghout"
73 results on '"Victoria Barghout"'

Search Results

1. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis

2. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center

Catalog

Books, media, physical & digital resources

3. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib

4. Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib

6. Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis

7. Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic–clonic seizures in the United States

8. Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States

9. Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA

10. Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer

11. Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States

12. First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study

13. Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study

14. Real-world adherence in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) or regorafenib (REG)

15. Comparison of the real-world adherence and compliance patterns with trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC)

16. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia

17. Irritable Bowel Syndrome, Health Care Use, and Costs: A U.S. Managed Care Perspective

18. [Untitled]

19. Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC)

20. Real-world dosing patterns of everolimus-based lines of therapy among post-menopausal women with hormone receptor-positive and human epidermal growth factor receptor-negative (HR+/HER2-) metastatic breast cancer (mBC)

21. A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer

22. Analysis of real world patient compliance to everolimus-based therapy among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC)

23. Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among post-menopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC)

24. Isolation of Less Polar Alkali-Labile Glycolipids of Human Brain by High-Speed Countercurrent Chromatography

25. Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag

26. Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study

27. PCN19 BUDGET IMPACT ANALYSIS OF SARGRAMOSTIM USE IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA

28. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database

29. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer

30. Direct medical costs of constipation in the United States

31. Tegaserod treatment for IBS: a model of indirect costs

32. Total costs of IBS: employer and managed care perspective

33. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population

34. Budget impact of tegaserod on a managed care organization formulary

35. Impairment in work productivity and health-related quality of life in patients with IBS

36. Quality of life in managed care patients with irritable bowel syndrome

37. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome

38. The economic consequences of irritable bowel syndrome: a US employer perspective

39. A comparison of office-based physician visits for irritable bowel syndrome and for migraine and asthma

40. Costs of care for irritable bowel syndrome patients in a health maintenance organization

41. Gastroparesis Impacts Health Care Resource Utilization

43. TEGASEROD THERAPY REDUCES GI-RELATED RESOURCE UTILIZATION

44. Identifying IBS patients using Rome II symptom criteria: 3- or 12-month reporting?

45. Prevalence of GI related surgical procedures among medicaid eligible patients with and without irritable bowel syndrome

46. Retrospective claims database cost analysis of second-line sorafenib (SR) or sunitinib (SR) therapy in treatment of patients (pts) with renal cell carcinoma (RCC)

47. Retrospective health care claims database analysis of direct medical costs of newly diagnosed patients (pts) with hepatocellular carcinoma (HCC) in the United States

48. Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large U.S. health care claims databases

49. PCN53 RETROSPECTIVE US CLAIMS DATABASE ANALYSIS OF THE COST OF SEQUENCING OF SORAFENIB AND SUNITINIB IN THE TREATMENT OF PATIENTS WITH RENAL CELL CARCINOMA (RCC)

50. Retrospective claims database analysis of elderly compared with nonelderly patients (pts) with newly diagnosed hepatocellular carcinoma (HCC)